The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?   Read More

Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.    Read More

New York Attorney General Andrew Cuomo filed some salacious charges this morning, accusing Intel of using "illegal threats and collusion" to control the microprocessor market.    Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

At the end of September, we looked at analysts' price targets for the S&P 500 to see which stocks had the greatest expected gains in the months ahead.  So far, 3 out of the October 1 top 5 and 6 out of the top 10 are trading to the upside.   Here is the current list of 15 stocks expected to pop (and another 15 expected to drop).   Read More

Biotech investors will be closely watching results from Amgen on Wednesday. How should you game this stock into earnings?   Read More

In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.    Read More

The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.    Read More

When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.    Read More